ImmunityBio generated $38285000 in total revenue in Q4 2025, primarily from ANKTIVA product sales, as commercialization accelerated. Net loss attributable to common stockholders was $61944000, reflecting continued investment in R&D and commercialization activities.

ImmunityBio generated $32060000 in total revenue in Q3 2025 driven by net product sales of ANKTIVA while net loss narrowed compared to the prior year quarter.

ImmunityBio generated $26425000 in total revenue in Q2 2025 driven primarily by ANKTIVA product sales, while net loss attributable to common stockholders was $92555000 as operating costs remained elevated.

ImmunityBio achieved significant growth in the first quarter of 2025, with net product revenue increasing by 129% to $16.5 million, driven by strong sales of ANKTIVA. The company also saw a 150% increase in ANKTIVA unit sales volume compared to the previous quarter. The positive results were supported by the issuance of a permanent J-code for ANKTIVA and progress in the recombinant BCG Expanded Access Program.

ImmunityBio achieved net product revenue of approximately $7.2 million in Q4 2024, a 21% increase quarter-over-quarter. The company's net loss attributable to common stockholders significantly decreased to $59.2 million from $233.4 million in Q4 2023, primarily due to product revenue and fair value changes in convertible notes and warrant liabilities.

ImmunityBio reported a net product revenue of approximately $6.0 million during the three months ended September 30, 2024, surpassing net product revenue of $1.0 million in the prior quarter and analyst estimates. The company's cash and marketable securities position was $130.4 million as of September 30, 2024.